相关实验视频
Updated: Jun 12, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
805
在双重抗血小板治疗期间,阿司匹林-蒂卡格勒和阿司匹林-克洛皮多格勒之间的尿酸升高的比较
International journal of clinical pharmacology and therapeutics
|September 18, 2024
概括
阿司匹林-蒂卡格勒洛尔治疗与阿司匹林-克洛皮多格雷尔相比,与更高的血清尿酸水平有关. 建议对尿酸进行监测,特别是对于患有脏问题或服用利尿剂的患者.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 双重抗血小板治疗 (DAPT) 是急性冠状动脉综合征后的关键.
- 阿司匹林与蒂卡格勒勒或克洛皮多格勒结合是常见的DAPT疗法.
- 潜在的代谢副作用的DAPT证书调查.
研究的目的:
- 为了比较服用阿司匹林-蒂卡格雷勒与服用阿司匹林-克洛皮多格雷尔的患者之间的血清尿酸 (SUA) 水平.
- 在接受DAPT的患者中识别与SUA升高相关的因素.
主要方法:
- 追溯队列研究的设计.
- 在2013年至2020年期间对41,877名患者的分析.
- 在6个月的随访期间,基线和最大SUA水平的比较.
主要成果:
- 阿司匹林-蒂卡格勒勒组显示显著更高的SUA水平 (OR 1.36;95% CI 1.15-1.60;p < 0.001).
- 功能障碍和利尿剂的使用被确定为SUA升高的危险因素.
- 两组之间没有发现基线SUA水平的显著差异.
结论:
- 与阿司匹林-克洛皮多格雷尔相比,阿司匹林-蒂卡格雷尔疗法与增加的SUA水平有关.
- 对于服用阿司匹林-蒂卡格雷勒的患者,建议对SUA进行监测.
- 应特别注意患有功能障碍或服用利尿剂的患者.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649

